• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 5, 2022

View Archived Issues

Biopharmas keep on keeping on, despite mounting omicron infections

Just as the world appeared to be winning the battle against COVID-19, the rules of the game changed. Omicron and concerns about future variants flipped the board. Vaccines and monoclonal antibodies are attracting fresh scrutiny as SARS-CoV-2 evolves. Cases are climbing closer to the highest levels recorded since the pandemic began. Antivirals are aiming to fill treatment gaps, but whether they will or not is about as clear as the virus’ next move. Read More

Drug, device companies accused of aiding terrorists to face further scrutiny

Be careful who you’re doing business with. That’s the warning the U.S. Court of Appeals for the District of Columbia Circuit sent this week to multinational drug and device companies doing business in terrorist hot spots around the world. Reversing a lower court, the D.C. Circuit cleared the way Jan. 4 for 21 drug and device companies to potentially be held accountable for doing business with Jaysh al-Mahdi terrorists, operating through the Iraqi Ministry of Health, who injured or killed hundreds of U.S. troops and civilians in Iraq. Read More
Teen receiving vaccine

ACIP on board with boosters for adolescents

Once the CDC accepts the recommendation of its Advisory Committee on Immunization Practices (ACIP), the COVID-19 vaccine regimen, at least for the Pfizer Inc.-Biontech SE vaccine, will include a booster dose for everyone 12 and older. ACIP voted 13-1 at a Jan. 5 emergency meeting to recommend the booster dose for 12- to 17-year-olds at least five months after a primary series of the Pfizer vaccine. Read More

Lupus, pneumonitis mar Annexon phase II data with C1q blocker in HD

Annexon Inc. deemed promising – as did analysts – the interim phase II data with C1q protein complex inhibitor ANX-005 in Huntington’s disease (HD), but the safety profile took Wall Street aback, and shares (NASDAQ:ANNX) sank $3.75, or 34%, to close at $7.26. Read More
Deal-puzzle-pieces

Amneal buys Saol’s baclofen portfolio in $83.5M deal

Amneal Pharmaceuticals Inc. has bought a small portfolio of drugs from fellow U.S. biotech Saol Therapeutics Inc., adding the skeletal muscle relaxant baclofen to its portfolio and boosting its pipeline with a potential therapy to treat spasticity in a deal worth $83.5 million plus royalties. Read More
Protai founders Kirill Pevzner and Eran Seger

Israel’s Protai comes out of stealth mode following $8M seed round

A new artificial intelligence (AI)-powered drug discovery startup, Protai Bio, has emerged from stealth mode following an $8 million seed round led by Grove Ventures and Pitango Healthtech that will see the new company develop a platform to accelerate drug discovery. Read More

Sperogenix licenses China rights to Santhera DMD candidate in $124M deal

Sperogenix Therapeutics Ltd. has acquired exclusive greater China rights to Santhera Pharmaceuticals Holding AG’s glucocorticoid analogue vamorolone in a deal worth up to $124 million. Read More

Appointments and advancements for Jan. 5, 2022

New hires and promotions in the biopharma industry, including: Adarx, Anthos, Bicycle, Blueprint, Boundless, Catalent, Chameleon, Crinetics, Diamedica, Disc Medicine, Elevar, Entrada, Escient, Galecto, Garuda, Gelesis, Hemab, Icosavax, Inscripta, Neuvivo, Oculis, Rapid Dose, Repare, Sellas, Spruce, Stada, T-knife, Travere. Read More

Financings for Jan. 5, 2022

Biopharmas raising money in public or private financings, including: Accro, Affinia, Atom, Avenge, Innate, Intra-Cellular, Korro, Life, Paramedica, Saliogen. Read More

In the clinic for Jan. 5, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, Aldeyra, Amryt, Anebulo, Astrazeneca, Belief, Bionomics, Concert, Humanigen, Kintor, Newamsterdam, Onquality, Orano Med, Orphomed, Pieris, Proqr, Radiomedix, Stuart, Union. Read More

Other news to note for Jan. 5, 2022

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Actinium, Alloy, Ares, Aveo, Biorchestra, Biohaven, Biontech, Champions, Covis, Cue, Cyclenium, Dotbio, Elicera, Epicentrx, Eversana, F-star, Genentech, Immunicum, Insilico, Intellia, Intravacc, Junshi, Kyverna, Lixte, LG Chem, Mannkind, Mdimune, Merck KGaA, Mindset, McQuade, Nanotic, Nikang, Novartis, Owp, PCI, Peptilogics, Pfizer, Prism, Roche, SK, Spectrum, Suono, Thirona, Twist, Vuja, Zynerba. Read More

Regulatory actions for Jan. 5, 2022

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Abbvie, Abionyx, Adverum, Akeso, Amylyx, Ananda, Astrazeneca, Cstone, Cullinan, Everest, Iliad, Genprex, Immix, Jazz, Knight, Melt, Nordic, Novavax, Oryzon, Pfizer, PTC, Spero, Splisense, Verseau, Viridian. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • Molecule illustration

    Unnatural Products joins Argenx in a $1.5B macrocyclic deal

    BioWorld
    Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • CMS logo and website

    CMS eyes competitive bidding for CGMs, insulin pumps

    BioWorld MedTech
    The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe